Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

Shared and distinct mechanisms of fibrosis.

Distler JHW, Györfi AH, Ramanujam M, Whitfield ML, Königshoff M, Lafyatis R.

Nat Rev Rheumatol. 2019 Dec;15(12):705-730. doi: 10.1038/s41584-019-0322-7. Epub 2019 Nov 11. Review.

PMID:
31712723
2.

Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study.

Jaeger VK, Tikly M, Xu D, Siegert E, Hachulla E, Airò P, Valentini G, Matucci Cerinic M, Distler O, Cozzi F, Carreira P, Allanore Y, Müller-Ladner U, Ananieva LP, Balbir-Gurman A, Distler JHW, Czirják L, Li M, Henes J, Jimenez SA, Smith V, Damjanov N, Denton CP, DelGaldo F, Saketkoo LA, Walker UA; EUSTAR co-authors .

Rheumatology (Oxford). 2019 Nov 4. pii: kez486. doi: 10.1093/rheumatology/kez486. [Epub ahead of print]

PMID:
31680161
3.

GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways.

López-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, Mumbach MR, Beretta L, Simeón CP, Carreira P, Ortego-Centeno N, Castellvi I, Bossini-Castillo L, Carmona FD, Orozco G, Hunzelmann N, Distler JHW, Franke A, Lunardi C, Moroncini G, Gabrielli A, de Vries-Bouwstra J, Wijmenga C, Koeleman BPC, Nordin A, Padyukov L, Hoffmann-Vold AM, Lie B; European Scleroderma Group†, Proudman S, Stevens W, Nikpour M; Australian Scleroderma Interest Group (ASIG), Vyse T, Herrick AL, Worthington J, Denton CP, Allanore Y, Brown MA, Radstake TRDJ, Fonseca C, Chang HY, Mayes MD, Martin J.

Nat Commun. 2019 Oct 31;10(1):4955. doi: 10.1038/s41467-019-12760-y.

5.

Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs.

Matei AE, Chen CW, Kiesewetter L, Györfi AH, Li YN, Trinh-Minh T, Xu X, Tran Manh C, van Kuppevelt T, Hansmann J, Jüngel A, Schett G, Groeber-Becker F, Distler JHW.

Ann Rheum Dis. 2019 Dec;78(12):1686-1692. doi: 10.1136/annrheumdis-2019-216108. Epub 2019 Sep 20.

PMID:
31540936
6.

Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis.

Codullo V, Cova E, Pandolfi L, Breda S, Morosini M, Frangipane V, Malatesta M, Calderan L, Cagnone M, Pacini C, Cavagna L, Recalde H, Distler JHW, Giustra M, Prosperi D, Colombo M, Meloni F, Montecucco C.

J Control Release. 2019 Sep 28;310:198-208. doi: 10.1016/j.jconrel.2019.08.015. Epub 2019 Aug 17.

PMID:
31430501
7.

Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual.

Fasano S, Riccardi A, Messiniti V, Caramaschi P, Rosato E, Maurer B, Smith V, Siegert E, De Langhe E, Riccieri V, Airó P, Mihai C, Avouac J, Zanatta E, Walker UA, Iannone F, García De la Peña Lefebvre P, Distler JHW, Vacca A, Distler O, Kowal-Bielecka O, Allanore Y, Valentini G.

Ann Rheum Dis. 2019 Dec;78(12):1681-1685. doi: 10.1136/annrheumdis-2019-215787. Epub 2019 Aug 17.

PMID:
31422354
8.

Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.

Soare A, Györfi HA, Matei AE, Dees C, Rauber S, Wohlfahrt T, Chen CW, Ludolph I, Horch RE, Bäuerle T, von Hörsten S, Mihai C, Distler O, Ramming A, Schett G, Distler JHW.

Arthritis Rheumatol. 2020 Jan;72(1):137-149. doi: 10.1002/art.41058.

PMID:
31350829
9.

Regulation of Fibroblast Apoptosis and Proliferation by MicroRNA-125b in Systemic Sclerosis.

Kozlova A, Pachera E, Maurer B, Jüngel A, Distler JHW, Kania G, Distler O.

Arthritis Rheumatol. 2019 Dec;71(12):2068-2080. doi: 10.1002/art.41041. Epub 2019 Nov 1.

PMID:
31309742
10.

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.

Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M.

Eur Respir J. 2019 Sep 19;54(3). pii: 1900161. doi: 10.1183/13993003.00161-2019. Print 2019 Sep. Review.

11.

Acyltransferase skinny hedgehog regulates TGFβ-dependent fibroblast activation in SSc.

Liang R, Kagwiria R, Zehender A, Dees C, Bergmann C, Ramming A, Krasowska D, Michalska-Jakubus M, Kreuter A, Kraner ME, Schett G, Distler JHW.

Ann Rheum Dis. 2019 Sep;78(9):1269-1273. doi: 10.1136/annrheumdis-2019-215066. Epub 2019 Jun 8.

PMID:
31177096
12.

Response to: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria' by Greco et al.

Knitza J, Cavagna L, Schett G, Distler JHW.

Ann Rheum Dis. 2019 Apr 17. pii: annrheumdis-2019-215484. doi: 10.1136/annrheumdis-2019-215484. [Epub ahead of print] No abstract available.

PMID:
30995979
13.

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.

Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network.

Ann Rheum Dis. 2019 Jul;78(7):979-987. doi: 10.1136/annrheumdis-2018-214816. Epub 2019 Apr 9.

PMID:
30967395
14.

Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ Complication.

Moinzadeh P, Kuhr K, Siegert E, Blank N, Sunderkoetter C, Henes J, Krusche M, Schmalzing M, Worm M, Schmeiser T, Günther C, Aberer E, Susok L, Riemekasten G, Kreuter A, Zeidler G, Juche A, Hadjiski D, Müller-Ladner U, Gaebelein-Wissing N, Distler JHW, Sárdy M, Krieg T, Hunzelmann N.

J Rheumatol. 2019 Apr 1. pii: jrheum.180582. doi: 10.3899/jrheum.180582. [Epub ahead of print]

PMID:
30936287
15.

PU.1 controls fibroblast polarization and tissue fibrosis.

Wohlfahrt T, Rauber S, Uebe S, Luber M, Soare A, Ekici A, Weber S, Matei AE, Chen CW, Maier C, Karouzakis E, Kiener HP, Pachera E, Dees C, Beyer C, Daniel C, Gelse K, Kremer AE, Naschberger E, Stürzl M, Butter F, Sticherling M, Finotto S, Kreuter A, Kaplan MH, Jüngel A, Gay S, Nutt SL, Boykin DW, Poon GMK, Distler O, Schett G, Distler JHW, Ramming A.

Nature. 2019 Feb;566(7744):344-349. doi: 10.1038/s41586-019-0896-x. Epub 2019 Jan 30.

16.

[New molecular mechanisms in the pathophysiology of rheumatic diseases].

Distler JHW.

Z Rheumatol. 2018 Nov;77(9):766-768. doi: 10.1007/s00393-018-0543-1. German. No abstract available.

PMID:
30382399
17.

The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis.

Zehender A, Huang J, Györfi AH, Matei AE, Trinh-Minh T, Xu X, Li YN, Chen CW, Lin J, Dees C, Beyer C, Gelse K, Zhang ZY, Bergmann C, Ramming A, Birchmeier W, Distler O, Schett G, Distler JHW.

Nat Commun. 2018 Aug 14;9(1):3259. doi: 10.1038/s41467-018-05768-3.

18.

Small Molecule Tyrosine Kinase Inhibitor Nintedanib Reduces Development of Cardiac Allograft Vasculopathy in Murine Aortic Allografts.

Gocht A, Spriewald B, Distler JHW, Ramsperger-Gleixner M, Ensminger SM, Weyand M, Heim C.

Transplant Direct. 2018 Jun 18;4(7):e367. doi: 10.1097/TXD.0000000000000804. eCollection 2018 Jul.

19.

Autoantibodies Recognizing Secondary NEcrotic Cells Promote Neutrophilic Phagocytosis and Identify Patients With Systemic Lupus Erythematosus.

Biermann MHC, Boeltz S, Pieterse E, Knopf J, Rech J, Bilyy R, van der Vlag J, Tincani A, Distler JHW, Krönke G, Schett GA, Herrmann M, Muñoz LE.

Front Immunol. 2018 May 7;9:989. doi: 10.3389/fimmu.2018.00989. eCollection 2018.

20.

Effects of different serotonin receptor subtype antagonists on the development of cardiac allograft vasculopathy in murine aortic allografts.

Gocht A, Distler JHW, Spriewald B, Ramsperger-Gleixner M, Weyand M, Ensminger SM, Heim C.

Transpl Immunol. 2018 Aug;49:43-53. doi: 10.1016/j.trim.2018.04.002. Epub 2018 Apr 9.

PMID:
29649585
21.

The non-neuronal cyclin-dependent kinase 5 is a fibrotic mediator potentially implicated in systemic sclerosis and a novel therapeutic target.

Wei J, Marangoni RG, Fang F, Wang W, Huang J, Distler JHW, Varga J.

Oncotarget. 2017 Dec 20;9(12):10294-10306. doi: 10.18632/oncotarget.23516. eCollection 2018 Feb 13.

22.

Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis.

Zhang Y, Pötter S, Chen CW, Liang R, Gelse K, Ludolph I, Horch RE, Distler O, Schett G, Distler JHW, Dees C.

Ann Rheum Dis. 2018 May;77(5):744-751. doi: 10.1136/annrheumdis-2017-212265. Epub 2018 Feb 3.

PMID:
29431122
23.

Targeting TGF-β signaling for the treatment of fibrosis.

Györfi AH, Matei AE, Distler JHW.

Matrix Biol. 2018 Aug;68-69:8-27. doi: 10.1016/j.matbio.2017.12.016. Epub 2018 Jan 31. Review.

PMID:
29355590
24.

Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis.

Yiğit B, Boyle M, Özler O, Erden N, Tutucu F, Hardy T, Bergmann C, Distler JHW, Adalı G, Dayangaç M, Mann DA, Zeybel M, Mann J.

Gut. 2018 Oct;67(10):1907-1908. doi: 10.1136/gutjnl-2017-315668. Epub 2018 Jan 20. No abstract available.

25.

Cutting Edge: Homeostasis of Innate Lymphoid Cells Is Imbalanced in Psoriatic Arthritis.

Soare A, Weber S, Maul L, Rauber S, Gheorghiu AM, Luber M, Houssni I, Kleyer A, von Pickardt G, Gado M, Simon D, Rech J, Schett G, Distler JHW, Ramming A.

J Immunol. 2018 Feb 15;200(4):1249-1254. doi: 10.4049/jimmunol.1700596. Epub 2018 Jan 12.

26.

Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators.

Matei AE, Beyer C, Györfi AH, Soare A, Chen CW, Dees C, Bergmann C, Ramming A, Friebe A, Hofmann F, Distler O, Schett G, Distler JHW.

Ann Rheum Dis. 2018 Mar;77(3):459. doi: 10.1136/annrheumdis-2017-212489. Epub 2018 Jan 8.

PMID:
29311148
27.

Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study.

Herrick AL, Peytrignet S, Lunt M, Pan X, Hesselstrand R, Mouthon L, Silman AJ, Dinsdale G, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk MC, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jobanputra P, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov NS, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman SM, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP.

Ann Rheum Dis. 2018 Apr;77(4):563-570. doi: 10.1136/annrheumdis-2017-211912. Epub 2018 Jan 6.

28.

Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study.

Peytrignet S, Denton CP, Lunt M, Hesselstrand R, Mouthon L, Silman A, Pan X, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuta C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, Inanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Herrick AL.

Rheumatology (Oxford). 2018 Feb 1;57(2):370-381. doi: 10.1093/rheumatology/kex410.

29.

Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study.

Hsu VM, Denton CP, Domsic RT, Furst DE, Rischmueller M, Stanislav M, Steen VD, Distler JHW, Korish S, Cooper A, Choi S, Schafer PH, Horan G, Hough DR.

J Rheumatol. 2018 Mar;45(3):405-410. doi: 10.3899/jrheum.161040. Epub 2017 Nov 1.

PMID:
29093152
30.

The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis.

Bergmann C, Brandt A, Merlevede B, Hallenberger L, Dees C, Wohlfahrt T, Pötter S, Zhang Y, Chen CW, Mallano T, Liang R, Kagwiria R, Kreuter A, Pantelaki I, Bozec A, Abraham D, Rieker R, Ramming A, Distler O, Schett G, Distler JHW.

Ann Rheum Dis. 2018 Jan;77(1):150-158. doi: 10.1136/annrheumdis-2017-211501. Epub 2017 Oct 25.

PMID:
29070530
31.

Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis.

Chakraborty D, Šumová B, Mallano T, Chen CW, Distler A, Bergmann C, Ludolph I, Horch RE, Gelse K, Ramming A, Distler O, Schett G, Šenolt L, Distler JHW.

Nat Commun. 2017 Oct 24;8(1):1130. doi: 10.1038/s41467-017-01236-6.

32.

Innate lymphoid cells and fibrotic regulation.

Horsburgh S, Todryk S, Ramming A, Distler JHW, O'Reilly S.

Immunol Lett. 2018 Mar;195:38-44. doi: 10.1016/j.imlet.2017.08.022. Epub 2017 Aug 24. Review.

PMID:
28844771
33.

Mapping and predicting mortality from systemic sclerosis.

Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, Riemekasten G, Airò P, Joven B, Vettori S, Cozzi F, Ullman S, Czirják L, Tikly M, Müller-Ladner U, Caramaschi P, Distler O, Iannone F, Ananieva LP, Hesselstrand R, Becvar R, Gabrielli A, Damjanov N, Salvador MJ, Riccieri V, Mihai C, Szücs G, Walker UA, Hunzelmann N, Martinovic D, Smith V, Müller CS, Montecucco CM, Opris D, Ingegnoli F, Vlachoyiannopoulos PG, Stamenkovic B, Rosato E, Heitmann S, Distler JHW, Zenone T, Seidel M, Vacca A, Langhe E, Novak S, Cutolo M, Mouthon L, Henes J, Chizzolini C, Mühlen CAV, Solanki K, Rednic S, Stamp L, Anic B, Santamaria VO, De Santis M, Yavuz S, Sifuentes-Giraldo WA, Chatelus E, Stork J, Laar JV, Loyo E, García de la Peña Lefebvre P, Eyerich K, Cosentino V, Alegre-Sancho JJ, Kowal-Bielecka O, Rey G, Matucci-Cerinic M, Allanore Y; EUSTAR group.

Ann Rheum Dis. 2017 Nov;76(11):1897-1905. doi: 10.1136/annrheumdis-2017-211448. Epub 2017 Aug 23.

PMID:
28835464
34.

Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.

Huang J, Maier C, Zhang Y, Soare A, Dees C, Beyer C, Harre U, Chen CW, Distler O, Schett G, Wollin L, Distler JHW.

Ann Rheum Dis. 2017 Nov;76(11):1941-1948. doi: 10.1136/annrheumdis-2016-210823. Epub 2017 Aug 16.

PMID:
28814429
35.

Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells.

Rauber S, Luber M, Weber S, Maul L, Soare A, Wohlfahrt T, Lin NY, Dietel K, Bozec A, Herrmann M, Kaplan MH, Weigmann B, Zaiss MM, Fearon U, Veale DJ, Cañete JD, Distler O, Rivellese F, Pitzalis C, Neurath MF, McKenzie ANJ, Wirtz S, Schett G, Distler JHW, Ramming A.

Nat Med. 2017 Aug;23(8):938-944. doi: 10.1038/nm.4373. Epub 2017 Jul 17.

36.

Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).

Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, Varga J, Coeck C, Gahlemann M, Sauter W, Schmidt H, Highland KB; SENSCIS™ trial investigators.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):75-81. Epub 2017 Jun 29.

37.

Tie2 as a novel key factor of microangiopathy in systemic sclerosis.

Moritz F, Schniering J, Distler JHW, Gay RE, Gay S, Distler O, Maurer B.

Arthritis Res Ther. 2017 May 25;19(1):105. doi: 10.1186/s13075-017-1304-2.

38.

Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis.

Beyer C, Huscher D, Ramming A, Bergmann C, Avouac J, Guiducci S, Meier F, Vettori S, Siegert E, Jaeger VK, Maurer B, Riemekasten G, Walker U, Müller-Ladner U, Valentini G, Matucci-Cerinic M, Allanore Y, Distler O, Schett G, Distler JHW.

Ann Rheum Dis. 2018 Apr;77(4):626-628. doi: 10.1136/annrheumdis-2016-210834. Epub 2017 May 11. No abstract available.

PMID:
28495672
39.

JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment.

Zhang Y, Liang R, Chen CW, Mallano T, Dees C, Distler A, Reich A, Bergmann C, Ramming A, Gelse K, Mielenz D, Distler O, Schett G, Distler JHW.

Ann Rheum Dis. 2017 Aug;76(8):1467-1475. doi: 10.1136/annrheumdis-2016-210911. Epub 2017 May 6.

PMID:
28478401
40.

Na+ deposition in the fibrotic skin of systemic sclerosis patients detected by 23Na-magnetic resonance imaging.

Kopp C, Beyer C, Linz P, Dahlmann A, Hammon M, Jantsch J, Neubert P, Rosenhauer D, Müller DN, Cavallaro A, Eckardt KU, Schett G, Luft FC, Uder M, Distler JH, Titze J.

Rheumatology (Oxford). 2017 Apr 1;56(4):674. doi: 10.1093/rheumatology/kex149. No abstract available.

41.

Epigenetic factors as drivers of fibrosis in systemic sclerosis.

Bergmann C, Distler JH.

Epigenomics. 2017 Apr;9(4):463-477. doi: 10.2217/epi-2016-0150. Epub 2017 Mar 27. Review.

PMID:
28343418
42.

Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.

Maier C, Ramming A, Bergmann C, Weinkam R, Kittan N, Schett G, Distler JHW, Beyer C.

Ann Rheum Dis. 2017 Jun;76(6):1133-1141. doi: 10.1136/annrheumdis-2016-210189. Epub 2017 Feb 16.

PMID:
28209630
43.

Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).

Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, Silman A, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Jobanputra P, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP.

Ann Rheum Dis. 2017 Jul;76(7):1207-1218. doi: 10.1136/annrheumdis-2016-210503. Epub 2017 Feb 10.

44.

Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling.

Chen CW, Beyer C, Liu J, Maier C, Li C, Trinh-Minh T, Xu X, Cole SH, Hsieh MH, Ng N, Althage A, Meeusen S, Pan S, Svensson EC, Seidel HM, Schett G, Gergely P, Harris JL, Distler JH.

Ann Rheum Dis. 2017 Apr;76(4):773-778. doi: 10.1136/annrheumdis-2016-210294. Epub 2017 Feb 2.

PMID:
28153829
45.

Analysis of ATP8B4 F436L Missense Variant in a Large Systemic Sclerosis Cohort.

López-Isac E, Bossini-Castillo L, Palma AB, Assassi S, Mayes MD, Simeón CP, Ortego-Centeno N, Vicente E, Tolosa C, Rubio-Rivas M, Román-Ivorra JA, Beretta L, Moroncini G, Hunzelmann N, Distler JHW, Riemekasten G, de Vries-Bouwstra J, Voskuyl AE, Radstake TRDJ, Herrick A, Denton CP, Fonseca C, Martín J.

Arthritis Rheumatol. 2017 Jun;69(6):1337-1338. doi: 10.1002/art.40058. Epub 2017 May 9. No abstract available.

46.

Na+ deposition in the fibrotic skin of systemic sclerosis patients detected by 23Na-magnetic resonance imaging.

Kopp C, Beyer C, Linz P, Dahlmann A, Hammon M, Jantsch J, Neubert P, Rosenhauer D, Müller DN, Cavallaro A, Eckardt KU, Schett G, Luft FC, Uder M, Distler JHW, Titze J.

Rheumatology (Oxford). 2017 Apr 1;56(4):556-560. doi: 10.1093/rheumatology/kew371. Erratum in: Rheumatology (Oxford). 2017 Apr 1;56(4):674.

47.

Update of EULAR recommendations for the treatment of systemic sclerosis.

Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Müller-Ladner U; EUSTAR Coauthors.

Ann Rheum Dis. 2017 Aug;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909. Epub 2016 Nov 9.

48.

Corrigendum: Evidence of innate lymphoid cell redundancy in humans.

Vély F, Barlogis V, Vallentin B, Neven B, Piperoglou C, Perchet T, Petit M, Yessaad N, Touzot F, Bruneau J, Mahlaoui N, Zucchini N, Farnarier C, Michel G, Moshous D, Blanche S, Dujardin A, Spits H, Distler JH, Ramming A, Picard C, Golub R, Fischer A, Vivier E.

Nat Immunol. 2016 Nov 16;17(12):1479. doi: 10.1038/ni1216-1479b. No abstract available.

PMID:
27849206
49.

The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc.

Liang R, Šumová B, Cordazzo C, Mallano T, Zhang Y, Wohlfahrt T, Dees C, Ramming A, Krasowska D, Michalska-Jakubus M, Distler O, Schett G, Šenolt L, Distler JH.

Ann Rheum Dis. 2017 Apr;76(4):756-764. doi: 10.1136/annrheumdis-2016-209698. Epub 2016 Oct 28.

PMID:
27793816
50.

Evidence of innate lymphoid cell redundancy in humans.

Vély F, Barlogis V, Vallentin B, Neven B, Piperoglou C, Ebbo M, Perchet T, Petit M, Yessaad N, Touzot F, Bruneau J, Mahlaoui N, Zucchini N, Farnarier C, Michel G, Moshous D, Blanche S, Dujardin A, Spits H, Distler JH, Ramming A, Picard C, Golub R, Fischer A, Vivier E.

Nat Immunol. 2016 Nov;17(11):1291-1299. doi: 10.1038/ni.3553. Epub 2016 Sep 12. Erratum in: Nat Immunol. 2016 Nov 16;17 (12 ):1479.

Supplemental Content

Loading ...
Support Center